AOD-9604 Research: What Published Studies Have Investigated

What is AOD-9604?

What is AOD-9604? It is a synthetic peptide corresponding to the C-terminal region of human growth hormone (residues 176-191), with an added N-terminal tyrosine — hence the common description hGH fragment 176-191. It emerged from work at Monash University and was advanced by Metabolic Pharmaceuticals in Australia as an investigational anti-obesity candidate; the “AOD” label is a historical “anti-obesity drug” code designation, stated here only as naming history. The research rationale that was investigated — not an established property — was to isolate the lipid-metabolism-associated portion of hGH apart from the intact hormone’s somatotropic, IGF-1-raising activity. That is a neutral molecular definition; the sections below describe what researchers examined, not effects in people.

Molecule properties

AOD-9604 is a 16-residue peptide: the C-terminal hGH-derived sequence spanning residues 176-191 with an N-terminal tyrosine addition. Because human growth hormone is a large 191-residue protein, isolating this short C-terminal stretch is what made the fragment tractable to synthesise and study on its own, and the added tyrosine is a defining structural detail that the literature uses to identify the molecule. In research catalogues it is supplied as a lyophilized powder, which is why it is handled as a research peptide rather than an intact hormone. Worth stating plainly is the distinction between this synthetic, research-grade fragment and the endogenous hormone from which its sequence is drawn — the fragment is a defined short peptide, not growth hormone itself, and the two should not be treated as interchangeable. These are molecule facts only, with no handling or reconstitution guidance.

Mechanisms researchers have examined

The AOD-9604 mechanism literature centres on lipid-metabolism signalling, examined largely in animal and cell models. Each direction below is framed as what researchers investigated:

• Lipolytic signalling in adipose tissue — Ng et al. (2000, Hormone Research) investigated a synthetic lipolytic domain of hGH (AOD9604) in obese Zucker rats and reported changes in adipose-tissue lipolytic activity, while in that model not showing the insulin-sensitivity impairment associated with chronic intact-hGH treatment. This is a reported preclinical observation, not a reader outcome.
• The beta-3 adrenergic receptor pathway — Heffernan et al. (2001, Endocrinology, PMID 11713213) examined human GH and AOD9604 in obese mice and in beta-3-adrenergic-receptor (β3-AR) knock-out mice, investigating whether lipid-metabolism effects were mediated through β3-AR signalling.
• Separation of lipolytic vs. somatotropic activity — a recurring research question across the program was whether the fragment could engage fat-metabolism pathways without raising IGF-1 or producing the growth and glucose effects of intact hGH. This was stated as an investigated hypothesis, not a settled result.

Read together, these directions share one framing question that the program kept returning to: could a defined fragment reproduce the lipid-metabolism-associated signalling attributed to growth hormone while leaving aside the hormone’s wider endocrine activity? The section closes as the literature does: these mechanisms were characterised primarily in cell and rodent models, the reported observations belong to those models rather than to people, and several of the proposed pathways remain under discussion. Each bullet names a pathway examined, not an effect in a reader.

Research models and the human clinical-trial history

On the preclinical side, the models are specific: obese Zucker rats in Ng et al. (2000), and genetically obese and β3-AR knock-out mice in Heffernan et al. (2001). These rodent and in-vitro systems supply most of the mechanistic record, and animal or cell findings cannot establish human outcomes.

Described neutrally as research history, AOD-9604 is one of the few compounds in this catalogue that advanced into human obesity trials. A multi-centre randomized, double-blind, placebo-controlled program was conducted in obese adults (Herd et al., Obesity Research, 2005, reporting the clinical study), and the compound moved through phase-2 development under Metabolic Pharmaceuticals. The honest and load-bearing fact is the outcome: the pivotal longer (24-week) human efficacy trial did not demonstrate statistically significant weight loss versus placebo, and the anti-obesity development program was discontinued in 2007 — a history summarised in the Valentino et al. (2010) review (Clinical Pharmacology & Therapeutics, PMID 20445536). Human safety and tolerability across the trial program were later reviewed by Stier et al. (2013, Journal of Endocrinology and Metabolism), reporting a tolerability profile in the studies described. Stated plainly: the human efficacy endpoint was not met. This is presented as research history, not as an outcome any reader would obtain, and the trials are not evidence of a benefit.

AOD-9604 among growth-hormone-derived fragments

In one line: what distinguished AOD-9604 as a research candidate was its design goal — isolating a lipid-metabolism-associated domain of human growth hormone — and the unusual fact that this goal was actually tested in humans rather than only in animals. That places it in a family-and-context relationship with intact hGH and with the broader growth-hormone-axis research peptides, framed as a research-focus comparison rather than any use or combination advice. For a related GH-axis metabolic research explainer, see tesamorelin research; for the secretagogue side of that axis, see CJC-1295 research and ipamorelin research. The comparison worth keeping in mind is a research one: intact hGH acts across a broad endocrine range, whereas AOD-9604 was studied as a narrowed fragment defined by a specific portion of that sequence, and the trials described above are what put that narrowing to an empirical test. This page deliberately hands off to those sibling pages rather than rebuilding their detail here.

Research-grade sourcing and verification

For laboratory research use only, AOD-9604 is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation at the lot level. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. This is sourcing and identity-assurance framing only, not an outcome claim.

Frequently asked questions

Literature cited

1. Ng FM, et al. “Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone.” Hormone Research. 2000;53(6):274-278.
2. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and beta(3)-AR Knock-Out Mice.” Endocrinology. 2001 Dec;142(12):5182-5189. PMID 11713213.
3. Herd C, Wittert G, Caterson L, Proietto J, Strauss B, Prins J, Stocks A, Vos E, Belyea C. “The effect of AOD9604 on weight loss in obese adults: Results of a randomized, double-blind, placebo-controlled, multicenter study.” Obesity Research. 2005 (NAASO annual meeting proceedings).
4. Valentino MA, Lin JE, Waldman SA. “Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy.” Clinical Pharmacology & Therapeutics. 2010 Jun;87(6):652-662. PMID 20445536.
5. Stier H, Vos E, Kenley D. “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.” Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15.